The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the ...

In addition to treatment of things like sleep apnea, the weight-loss drugs could lead to more joint replacements, said Sara ...

Revolutionary weight-loss drugs are transforming U.S. health care, prompting patients to seek diagnoses for obesity-related ...

Sleep apnea is a sleep disorder in which breathing repeatedly stops and starts during sleep. It can cause poor sleep quality, ...

Sleep apnea is a sleep disorder characterized by interrupted breathing. There are two main types of sleep apnea: obstructive ...

Weight-loss drugs are increasingly prescribed in the U.S., not only for obesity treatment but also to facilitate eligibility ...

The power of deep breathing for weight loss While seated ... Proof of the slimming power of sleep: A University of Chicago ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...